Studies have found that the mRNA expression level of BGN is increased in bladder, brain, central nervous system, breast, colorectal, esophageal, gastric, head and neck, and lung and ovarian cancer, including 28 subtypes of cancers compared with normal tissues. This evidence concerns the gene BGN and ovarian carcinoma.